BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» With three debuts in two weeks, HKEX's biotech IPO market remaining strong
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
With three debuts in two weeks, HKEX's biotech IPO market remaining strong
Nov. 1, 2019
By
Elise Mak
No Comments
BEIJING – After Suzhou, China-based
Ascentage Pharma Group International
launched a $53 million IPO on the Hong Kong Stock Exchange (HKEX) Monday,
Tot Biopharm International Co. Ltd.
, also from Suzhou, and
Sinomab Bioscience Ltd.
, of Hong Kong, will also debut on the bourse to reap as much as $87 million and $223.1 million, respectively, in the following two weeks.
BioWorld
Financings